38,406 Shares in Amgen Inc. $AMGN Acquired by Vise Technologies Inc.

Vise Technologies Inc. acquired a new position in shares of Amgen Inc. (NASDAQ:AMGN) during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 38,406 shares of the medical research company’s stock, valued at approximately $16,189,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. State Street Corp lifted its stake in shares of Amgen by 38.2% in the 2nd quarter. State Street Corp now owns 42,205,243 shares of the medical research company’s stock valued at $15,283,363,000 after purchasing an additional 11,656,755 shares during the last quarter. MW Advisory LLC purchased a new position in shares of Amgen in the 2nd quarter worth approximately $1,054,000. Baird Financial Group Inc. boosted its holdings in shares of Amgen by 1.6% in the 2nd quarter. Baird Financial Group Inc. now owns 339,825 shares of the medical research company’s stock worth $123,057,000 after purchasing an additional 5,496 shares during the period. MassMutual Private Wealth & Trust FSB increased its position in shares of Amgen by 105.8% during the 3rd quarter. MassMutual Private Wealth & Trust FSB now owns 13,514 shares of the medical research company’s stock valued at $5,696,000 after purchasing an additional 6,947 shares during the last quarter. Finally, Integrated Advisors Network LLC increased its position in shares of Amgen by 50.5% during the 1st quarter. Integrated Advisors Network LLC now owns 18,941 shares of the medical research company’s stock valued at $6,664,000 after purchasing an additional 6,356 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

AMGN has been the subject of a number of analyst reports. Weiss Ratings upgraded Amgen from a “buy (b)” rating to a “buy (b+)” rating in a research report on Thursday, October 8th. Robert W. Baird boosted their price objective on shares of Amgen from $215.00 to $230.00 and gave the company an “underperform” rating in a research report on Wednesday, August 5th. Wells Fargo & Company reduced their target price on shares of Amgen from $435.00 to $430.00 and set an “equal weight” rating on the stock in a research note on Monday, October 12th. UBS Group increased their target price on shares of Amgen from $430.00 to $470.00 and gave the company a “buy” rating in a research note on Friday, October 9th. Finally, HSBC lowered shares of Amgen from a “buy” rating to a “hold” rating and lowered their target price for the stock from $445.00 to $425.00 in a report on Thursday, September 10th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, sixteen have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Amgen has an average rating of “Hold” and an average price target of $389.71.

Amgen Price Performance

Amgen stock opened at $466.01 on Monday. The stock has a market cap of $251.94 billion, a price-to-earnings ratio of 28.96, a price-to-earnings-growth ratio of 3.41 and a beta of 0.43. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.13. Amgen Inc. has a 1 year low of $288.00 and a 1 year high of $475.65. The firm has a 50-day moving average of $419.96 and a two-hundred day moving average of $374.79.

Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, topping analysts’ consensus estimates of $5.62 by $0.67. The business had revenue of $10.05 billion for the quarter, compared to the consensus estimate of $9.43 billion. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The company’s revenue for the quarter was up 9.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $6.02 EPS. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, research analysts forecast that Amgen Inc. will post 22.96 earnings per share for the current year.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 11th. Investors of record on Friday, November 20th will be paid a $2.52 dividend. The ex-dividend date of this dividend is Friday, November 20th. This represents a $10.08 annualized dividend and a yield of 2.2%. Amgen’s dividend payout ratio is 62.65%.

Insider Activity at Amgen

In other Amgen news, SVP Rachna Khosla sold 2,000 shares of Amgen stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $412.57, for a total transaction of $825,140.00. Following the completion of the sale, the senior vice president directly owned 6,404 shares of the company’s stock, valued at $2,642,098.28. The trade was a 23.80% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Nancy A. Grygiel sold 2,970 shares of the company’s stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total value of $1,194,415.20. Following the completion of the sale, the senior vice president owned 7,340 shares of the company’s stock, valued at $2,951,854.40. This represents a 28.81% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 6,222 shares of company stock worth $2,540,926. 0.85% of the stock is owned by insiders.

Amgen Company Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company’s products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.